Botanix Pharmaceuticals (ASX:BOT) reported Wednesday a fiscal first-half loss of AU$0.017 per diluted share, wider compared with a loss of AU$0.0038 a year earlier.
Revenue for the six months ended Dec. 31, 2024, was AU$345.7 million, compared with AU$377.9 million a year earlier.
The company's shares fell 1% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.